UNSPSC 51161711: Mepixanox

This classification denotes an anti-asthmatic agent with the molecular formula C20H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7419T4YQQW, chemically known as 9h-xanthen-9-one, 3-methoxy-4-(1-piperidinylmethyl)- but generally known as mepixanox, which bears US NIH Compound Identifier 65687. European Medicines Agency schedules Mepixanox in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08754MIG.

UNSPSC 51161711 Mepixanox, a Commodity code, covers pharmaceutical products and drug-related systems that state and local governments procure for public health, employee health benefit, and emergency response programs. Recent state and local solicitations under this code show demand for naloxone supply and safe drug deactivation systems for community health initiatives, on-site pharmacy services for government employee health plans, generic pharmaceutical products for multi-state cooperative purchasing, and direct-to-manufacturer prescription programs to optimize cost management. Issuing bodies span county health departments, county government employee health benefit programs, state health agencies, and multistate cooperative purchasing alliances, with Seminole County Florida, Hall County Georgia, the Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance appearing in recent opportunities. The work ranges from product procurement and logistics for emergency response supplies to vendor-managed pharmacy operations serving hundreds of government employees and their families.

Recent activity concentrates in Florida, Georgia, Texas, and Minnesota. Seminole County Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a response deadline of July 26, 2023, through competitive bidding with quarterly deliveries to the county community health building. Hall County Georgia released RFQ/P #47-010 in May 2026 for on-site pharmacy services at the county family health center clinic in Gainesville, serving approximately 3,005 plan members across multiple health plan types, with proposals due June 4, 2026, evaluated 80/20 on technical qualifications and cost. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription program capabilities, with no formal response deadline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP for generic multi-source pharmaceuticals and OTC products in January 2026 with proposals due March 26, 2026, requiring distribution through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with awards effective July 1, 2026.